Brampton Civic Hospital is an acute care hospital in Brampton, Ontario and part of the William Osler Health System. It is a community teaching hospital for the Michael G. DeGroote School of Medicine of McMaster University.

There are 608 beds in William Osler Health System.

During the past decade, William Osler Health System conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 8 clinical trials were completed, i.e. on average, 18.6% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 8 clinical trials were completed. i.e. 38.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "William Osler Health System" #1 sponsor was "NCIC Clinical Trials Group" with 6 trials, followed by "Gilead Sciences" with 4 trials sponsored, "Hoffmann-La Roche" with 4 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored and "Alliance for Clinical Trials in Oncology" with 4 trials sponsored. Other sponsors include 38 different institutions and companies that sponsored additional 40 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "William Osler Health System" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 6 trials as a collaborator, "NCIC Clinical Trials Group" with 6 trials as a collaborator, "National Cancer Institute (NCI)" with 5 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator and "William Osler Health System" with 3 trials as a collaborator. Other collaborators include 77 different institutions and companies that were collaborators in the rest 80 trials.

According to Clinical.Site data, the most researched conditions in "William Osler Health System" are "Breast Cancer" (6 trials), "Bladder Cancer" (3 trials), "Colorectal Cancer" (3 trials), "Lung Cancer" (3 trials) and "Non-Small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "William Osler Health System" in a lesser frequency.

Most popular intervention types in "William Osler Health System" are "Drug" (44 trials), "Other" (13 trials), "Biological" (8 trials), "Device" (5 trials) and "Genetic" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Carboplatin" (5 trials), "Cisplatin" (3 trials), "Docetaxel" (3 trials) and "Pembrolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "William Osler Health System" are 59 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "William Osler Health System". undefined are not yet recruiting, 13 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in William Osler Health System, 1 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in William Osler Health System, 1 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 11 trials that are defined as “Not Applicable".